JPH09505561A - 神経系の遺伝子治療 - Google Patents

神経系の遺伝子治療

Info

Publication number
JPH09505561A
JPH09505561A JP7510881A JP51088195A JPH09505561A JP H09505561 A JPH09505561 A JP H09505561A JP 7510881 A JP7510881 A JP 7510881A JP 51088195 A JP51088195 A JP 51088195A JP H09505561 A JPH09505561 A JP H09505561A
Authority
JP
Japan
Prior art keywords
cells
vector
nervous system
tumor
producer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7510881A
Other languages
English (en)
Japanese (ja)
Inventor
ラム，ツヴァイ
ブレーズ，アール．，マイケル
オールドフィールド，エドワード，エッチ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Government
Original Assignee
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Government filed Critical US Government
Publication of JPH09505561A publication Critical patent/JPH09505561A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP7510881A 1993-10-01 1994-09-28 神経系の遺伝子治療 Pending JPH09505561A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13108593A 1993-10-01 1993-10-01
US08/131,085 1993-10-01
PCT/US1994/010977 WO1995009654A1 (en) 1993-10-01 1994-09-28 Gene therapy of the nervous system

Publications (1)

Publication Number Publication Date
JPH09505561A true JPH09505561A (ja) 1997-06-03

Family

ID=22447805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7510881A Pending JPH09505561A (ja) 1993-10-01 1994-09-28 神経系の遺伝子治療

Country Status (4)

Country Link
EP (1) EP0723460A4 (de)
JP (1) JPH09505561A (de)
CA (1) CA2171109A1 (de)
WO (1) WO1995009654A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160035596A (ko) * 2013-07-26 2016-03-31 유니버시티 오브 아이오와 리써치 파운데이션 뇌 질환을 치료하기 위한 방법 및 조성물

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707071B1 (de) 1994-08-16 2003-07-30 Crucell Holland B.V. Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
WO1998032869A1 (en) * 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
EP1061806A4 (de) * 1998-03-12 2001-09-12 Univ Pennsylvania Produktive zellen für replikationsselektive viren zur behandlung bösartiger erkrankungen
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
RU2245366C2 (ru) 1999-04-30 2005-01-27 Чирон С.Р.Л. Антиген neisseria, кодирующая его нуклеиновая кислота, их использование
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB2397063A (en) * 1999-10-21 2004-07-14 Cedars Sinai Medical Center A medicament comprising a cytotoxic pro drug activated by HSV TK
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
EP2275552B1 (de) 1999-10-29 2015-09-09 GlaxoSmithKline Biologicals SA Antigenpeptide aius Neisseria
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
PT1736541E (pt) 2004-03-29 2013-01-31 Galpharma Co Ltd Nova proteína galectina 9 modificada e sua utilização
US8420611B2 (en) 2004-08-12 2013-04-16 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
WO2008095027A2 (en) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
EP4208718A1 (de) 2020-09-02 2023-07-12 Johansson Swartling, Fredrik Vorhersage eines krebsrezidivs und behandlung von krebserkrankungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051288C (en) * 1990-09-14 2002-02-05 Robert L. Martuza Viral targeted destruction of neoplastic cells
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160035596A (ko) * 2013-07-26 2016-03-31 유니버시티 오브 아이오와 리써치 파운데이션 뇌 질환을 치료하기 위한 방법 및 조성물

Also Published As

Publication number Publication date
EP0723460A1 (de) 1996-07-31
CA2171109A1 (en) 1995-04-13
EP0723460A4 (de) 1998-09-30
WO1995009654A1 (en) 1995-04-13

Similar Documents

Publication Publication Date Title
JPH09505561A (ja) 神経系の遺伝子治療
WO1995009654A9 (en) Gene therapy of the nervous system
EP2077862B1 (de) Dosierung einer krebstherapie
JPH06509943A (ja) 移植したレトロウイルス産生細胞を用いるインビボでの遺伝子導入
JPH08507687A (ja) 遺伝子治療用の改良されたベクター
EP0689601A1 (de) Verfahren zur herstellung von helfer-freien retroviren mit hohem titer durch transienten transfektionen
JP2009112314A (ja) 疾患を処置するための方法および組成物
JP2000514652A (ja) 産生能力の高いカプシド化系
US7871819B2 (en) Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
WO1995034639A1 (en) Novel retroviral envelope and ltr and retroviral vector particles including such envelope and/or ltr
JPH09511405A (ja) レトロウイルスベクターハイブリッド及びその遺伝子転移のための使用
US20090123428A1 (en) Pathotropic targeted gene delivery system for cancer and other disorders
EP2062971A1 (de) Chimäres adenovirus, verfahren zur herstellung davon und pharmazeutikum mit verwendung davon
CA2169557A1 (en) Treatment of human tumors by genetic transformation of human tumor cells
CA2208210A1 (en) Retroviral vectors for expression in embryonic cells
JPH11514209A (ja) 組換えレトロウイルス調製物による造血幹細胞の高効率エクスビボ形質導入
US5837536A (en) Expression of human multidrug resistance genes and improved selection of cells transduced with such genes
US6743631B1 (en) Use of human serum resistant vector particles and cell lines for human gene therapy
WO2000029589A9 (en) Methioninase gene therapy for tumor treatment
Slama et al. Gene transfer
JP4508656B2 (ja) 腫瘍を死滅させるための組成物および方法
JPH10512276A (ja) 遺伝子治療による治療薬の送達
Zhang et al. MOLECULAR TARGETING OF CANCER: RETROVIRAL VECTOR-MEDIATED ANTISENSE NUCLEIC ACID THERAPY
Dumey et al. Feasibility Study Intended for In Vivo Retroviral Mediated Gene Transfer of Bladder Urothelium
Vile et al. Retroviral Vectors From Laboratory Tools to Molecular Medicines